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Abstract Ten years after the publication of the position
paper ‘‘The hallmarks of cancer’’ (Hanahan and Weinberg
Cell 100:57–70, 2000), it has become increasingly clear
that mutated cells on their way to giving rise to a tumor
have also to learn how to thrive in a chronically inflamed
microenvironment, evade immune recognition, and sup-
press immune reactivity. Genetic and molecular definition
of these three immune hallmarks of cancer offers the
opportunity to learn how to deploy specific countermea-
sures to reverse the situation in favor of the immune system
and, eventually, the patient. This new information could be
channeled to address what seem to be the three major
hallmarks for the immune control of cancer progression:
effective procedures to activate immune reactivity; char-
acterization of not-disposable oncoantigens; and counter-
action of immune suppression.
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The immune hallmarks of cancer
In an important position paper published in January 2000,
Hanahan and Weinberg listed six alterations essential for
malignant growth: self-sufficiency in growth signals,
insensitivity to antigrowth signals, limitless replicative
potential, ability to evade apoptosis, sustained angiogene-
sis, and ability to invade the tissues and metastasize [1].
The ability to deal with immune mechanisms, however,
was not included among these essential capabilities, but
may be supposed to be acquired by most—and perhaps
all—tumors. Because of the authoritative impact of this
paper, these six hallmarks are usually quoted as the starting
ground for new anticancer strategies, while the addition of
other critical features of malignant tumors as hallmarks is
often urged [2].
In the 10 years since the publication of the paper, it has
become increasingly clear that both exploitation of immune
mechanisms and evasion of immune surveillance are skills
that cancer cells should acquire on their way to giving rise
to a tumor. A comprehensive cellular, molecular, and
genetic interpretation of the initially somewhat fuzzy evi-
dence of the importance of such acquisition has also been
worked out. Three such immune hallmarks are certainly
required:
1. Ability to thrive in a chronically inflamed
microenvironment
2. Ability to evade immune recognition
3. Ability to suppress immune reactivity
These three capabilities and acquisition of the genetic
changes required to put them into practice are constant and
essential features of natural and experimental cancers.
Their strength, however, may vary from one kind of tumor
to another, and even more variable are the mechanisms
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through which the various types of cancer undertake these
activities. Acquisition of a specific genome change, there-
fore, is not important, whereas acquisition of these capa-
bilities is crucial, irrespective of the mechanisms involved.
Ability to thrive in a chronically inflamed
microenvironment
Genetically modified mouse models show the intrinsic
carcinogenic potency of inflammation [3–5] and permit
molecular definition of several of the mechanisms whereby
an incipient tumor takes advantage of an inflammatory
microenvironment. Continual activation of leukocyte pop-
ulations, triggered by unrelenting infections, tissue damage
or the anomalous behavior of the mutated cells, contributes
to the progression of neoplastic transformation with mul-
tiple mechanisms that range from reactive oxygen species
to growth and angiogenic factors [6]. The balance between
immunity and inflammation is constantly altered during
aging, with inflammation holding the center of the stage in
old age when tumor incidence peaks [7, 8].
The importance of an inflammatory microenvironment
is so strong that even the time frame within which an
oncogene-addicted cell population gives rise to a tumor in
transgenic mice is modulated by the reactive stroma that
surrounds the cancer lesion [9]. Inflammation and carci-
nogenesis are linked even in the absence of external
inflammatory stimuli. Oncogene-driven signals activate
intrinsic pro-inflammatory pathways that affect the time
frame within which a carcinoma appears and progresses [6,
10]. Genome-wide microarray analysis in transgenic mice
identifies cytokine genes whose increased expression in the
tumor microenvironment is naturally induced by the
transformed cells and required for their progression [11].
The inflammatory cytokines produced can be both involved
in autocrine loops directly fueling tumor cell proliferation
[12] and released by immune/inflammatory cells recruited
to the site of epithelial transformation [13]. Inhibition of
the NF-kB pathway in these immune cells modifies stroma
cell components and limits tumor expansion [14, 15].
Murine molecular data are directly endorsed by many
epidemiological studies in humans that link extrinsic and
intrinsic inflammatory pathways with an increased risk of
cancer [16]. The increased risk of gastric cancer in the
setting of bacterial infections is linked to the polymor-
phisms in genes coding for pro-inflammatory cytokines
[17]. These findings show how extrinsic and intrinsic
inflammatory pathways conspire along the road to cancer.
Molecular definition of the ways in which chronic
inflammation contributes to viral, chemical, and intrinsic
carcinogenesis in humans is opening up novel prospects for
immunoprevention.
Ability to evade immune recognition
The immune surveillance theory was put forward in the
1960s. It defined the ability to identify and destroy nascent
tumors as a central asset of the immune system [18, 19],
but later received an apparently deadly blow when no
increase in tumor incidence was observed in athymic nude
mice [20, 21]. Work in the last 10 years, however, has
shown that these mice are not an appropriate model for the
investigation of immune surveillance, while the employ-
ment of genetically modified mice to generate defined and
stable immune defects has fully vindicated this theory.
Mice with genetic alterations leading to complete T- and
B-cell deficiencies are more prone to spontaneous and
chemical carcinogenesis than wild-type mice [22]. Addi-
tional gene defects affecting natural immune responses
increase the risk of more aggressive and precocious tumors
[22]. Moreover, immune mechanisms hold occult cancer at
bay for periods equivalent to the natural life span of the
mouse, while temporary immunodepression allows it to
progress [23].
Immune surveillance mechanisms limit cancer devel-
opment, but are not completely efficient. Tumors that
eventually arise are those that are poorly or not-immuno-
genic [24]. A critical feature that distinguishes occult
neoplastic lesions from overt cancer is thus their suscep-
tibility to immune control. The ability to evade is another
hallmark of cancer.
Data from patients with acquired immune deficiencies
such as AIDS and post-transplant immune suppression
show a dramatic increase in the incidence of several tumor
types, including lung cancer, lymphoid tumors and tumors
related to viral infections, such as Kaposi’s sarcoma
(human herpes virus-8) and anogenital carcinomas (human
papilloma virus, HPV) [25].
In the last 10 years, it has become evident that a tumor
becomes aware of its susceptibility to immune attack and
elaborates many defenses against it. These have now been
defined in both cellular and molecular terms.
The increasing instability of the genome of precancerous
cells favors the emergence of clones of different immuno-
genicity. The poorly immunogenic ones are those that sneak
through the meshes of immunosurveillance. The stealthi-
ness of clinical tumors can be seen as one of the results of an
effective immunosurveillance [24]. The loss or rarefaction
of the expression of the glycoproteins of the major histo-
compatibility complex (MHC) on the cell membrane is one
of the mechanisms by which tumor stealthiness is acquired.
In addition, it may result from the subversion of cell
physiology as a consequence of the overexpression of
oncogene-coded proteins [26, 27], and alteration of anti-
genic peptide-processing machinery [28, 29].
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Poor MHC glycoprotein expression and hampered
antigenic peptide expression on the tumor cell surface
frustrate direct recognition of tumor antigens by T cells and
impede direct priming of an immune response by a tumor.
Moreover, they make the effector phase of the T-cell
reaction against tumor-associated antigens worthless.
Blockage of these two functions is a crucial issue in tumor
development since T-cell-mediated cytotoxicity is an
effective mechanism of tumor inhibition.
Ability to suppress immune reactivity
As their growth hidden from immune recognition is not
enough to allay their obsession with attacks on the part of
the immune system, most—all?—tumors acquire the abil-
ity to release a series of factors and cytokines to subvert
normal reaction mechanisms. When a tumor acquires the
ability to release significant amounts of the colony-stimu-
lating factors [30] or the vascular endothelial growth factor
[31], it causes the expansion of a population of myeloid
immature cells that may not only help tumors to suppress
immune reaction but also aid in the construction of new
blood vessels for tumor growth [32, 33].
Yet even this is not enough. Through direct release of
transforming growth factor (TGF)-beta, IL-10, and in-
doleamine 2,3-dioxygenase (IDO), or through the activa-
tion of such secretions in myeloid-derived suppressor cells,
tumor-associated macrophages and dendritic cells, a tumor
converts naı¨ve T cells into adaptive regulatory T (TReg)
cells. Expansion of these cells is another way by which a
tumor holds back host reactivity [34].
Tumors also exploit the physiologic role of natural TReg
cells to block immune reactions. These cells recognize with
high affinity self-antigens and block the induction of
autoimmunity. The overexpression of a few tolerated self-
antigens, as happens during the expansion of tumor cells
overexpressing oncogene products, leads to the activation
of natural TRegs. Thus, both through the exploitation of a
physiologic safeguard mechanism to control autoimmunity
and the ability to convert naı¨ve T cells into a suppressor
population, a growing tumor biases the immune response
toward immunosuppression. The activation of adaptive and
natural TReg cells is triggered by specific activation of their
T-cell receptor. The TReg suppressor mechanisms thus
turned on are mediated by different functions:
(a) Exposure on the cell membrane of molecules delivering
negative signals (CTLA4 and LAG3) to dendritic cells.
These signals inhibit the maturation of dendritic cells,
block their expression of MHC and co-stimulatory
molecules (CD80 and CD86) [35], activate their ability
to produce IDO that leads to the generation of the
immunosuppressive mediator kynurenine, and indi-
rectly suppress genes encoding IL-6 and TNF [36].
(b) Release of adenosine and the secretion of TGF-b, IL-
10, and IL-35 that interfere with the activation and
effector functions of T cells [35, 37].
(c) Secretion of granzymes and perforin that might have
cytolytic effects on target T cells, as well as on
dendritic cells [35].
The same group of signals triggers the activation and
maintenance of anomalous functions of tolerogenic den-
dritic cells and tumor-associated macrophages. In this way,
a growing tumor orchestrates a web of distinct but inte-
grated suppressive activities.
How to counteract the immune hallmarks of cancer
The knowledge gained in the last 10 years offers the
opportunity to learn how to deploy specific countermea-
sures to reverse the situation in favor of the immune system
and, eventually, the patient. This new information could be
channeled to address what seem to be the three major
hallmarks for the immune control of cancer progression:
1. Effective procedures to activate immune reactivity
2. Characterization of not-disposable oncoantigens
3. Counteract immune suppression.
Effective procedures to activate immune reactivity
Chronic inflammation can be dampened with anti-inflam-
matory drugs, which in some cases reduce the risk of
cancer (sulindac, aspirin) [38]. However, a more sensitive
strategy is to re-orient inflammation from tumor promotion
to a tumor-preventive reaction [39–41]. Both passive
(antibodies) and active (vaccines) immunization effectively
protect the host from tumor onset [42, 43]. However, a
much larger body of evidence favors active immunization.
The high efficacy of vaccines in the prevention of
infection by carcinogenic viruses and other infectious
agents causing cancer is currently getting an extraordinary
social impact. Vaccines aimed at removing an infective
risk factor are being commonly used.
Hepatocellular carcinoma accounts for more than 4% of
all human cancers, and 80% of cases are associated with viral
infection. Vaccination against hepatitis B virus (HBV)
markedly reduced the incidence of post-hepatitis hepato-
cellular carcinoma [44]. Since chronic inflammation plays a
significant role in the onset of liver cancer that follows HBV
infection, this vaccine can be viewed as a form of primary
prevention of a carcinogenic chronic inflammation.
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HPV causes neoplastic disorders ranging from benign
warts to malignant cervical and anogenital carcinomas
[45]. The worldwide implementation of vaccination pro-
grams against HPV began only a few years ago, and their
long-term efficacy in the prevention of cervical carcinoma
is not yet completely assessed. Initial results are extremely
favorable, and almost complete prevention of carcinogen-
esis is foreseen [46]. Current HPV vaccines are effective in
cancer prevention but devoid of therapeutic efficacy.
Vaccines able to cure cervical carcinomas are actively
studied [47].
The Epstein–Barr virus (EBV) is implicated in a variety
of diseases worldwide: infectious mononucleosis in Wes-
tern countries, nasopharyngeal carcinoma in Asia, Burkitt’s
lymphoma in Africa, and lymphoproliferative diseases in
immunodeficient patients. The use of some promising
candidate vaccines is being actively pursued [48, 49].
While vaccines to prevent tumors related to an infec-
tious agent are becoming a medical reality, a large series of
studies on genetically engineered mice suggest that vac-
cines to prevent tumors not related to an infectious agent
may also be a new form of prevention [50, 51]. Numerous
data on healthy mice carrying oncogenes that predestine to
lethal cancer show that vaccines addressing oncogene
products block the onset of neoplastic lesions. Repeated
boosts of the vaccine afford a persistent protection that may
last as long as the natural murine life span.
Somewhat surprisingly, the T-cell-mediated cytotoxic
response plays a minor role in the protection afforded by
several of these vaccines. Since the target oncogene
products are self molecules, they elicit a kind of split-tol-
erance that mainly causes the disappearance of high-
affinity CD8? T cells [52]. In addition, this response is
inhibited by the expansion of natural TReg cells that rec-
ognize the target antigen as a self-protein [53]. Therefore,
most of the antitumor action elicited by preventive vac-
cines rests on the multiple direct and indirect antitumor
activities of antibodies [54–56].
Characterization of not-disposable oncoantigens
Vaccines that must elicit and sustain a virtually lifelong
immune response carry the risk of downmodulation or loss
of the target antigen by neoplastic cells. A suitable target
antigen that preempts the loss of immune recognition
should
(a) have an essential role in tumor growth or progression;
(b) be a target of cytotoxic cells and antibodies.
We have chosen the term ‘‘oncoantigens’’ for tumor
antigens that fulfill these two requirements [50]. When
carcinogenesis is driven by an oncoantigen, antigen-loss
variants can occur, but their tumorigenic potential would
be markedly impaired [57, 58]. In the later course of tumor
progression, the driving role of the targeted oncogene can
be taken by different genes [59, 60], whose products, in
turn, will offer further oncoantigen targets.
Tumors evade T-cell recognition through the down-
modulation of antigen-processing machinery and MHC
glycoprotein expression. However, antibody recognition of
accessible molecules is not affected, and antibodies still
ensure a functional inhibition of the target oncoantigen
together with the activation of complement-mediated
cytotoxicity and ADCC. Class I oncoantigens expressed on
the cell surface can be attacked by both antibodies and cell-
mediated immunity and are probably the best target for a
preventive vaccine [50]. Class II oncoantigens are tumor-
secreted molecules or molecules in the tumor microenvi-
ronment that play essential roles in tumor expansion [61].
These can be targeted by antibodies but not by T-cell-
mediated immunity. Class III oncoantigens are tumor
molecules that cannot be reached by antibodies because of
their intracellular localization, and thus can only be tar-
geted by T cells [62, 63].
One could imagine that in the future, vaccines to prevent
cancer will be administered to the general population, as is
happening now to prevent infectious tumors. In a more
realistic perspective, there are several human groups at risk
of cancer that could benefit from specific vaccines, espe-
cially in the case of genetic risk, preneoplastic syndromes,
cohorts of individuals previously exposed to environmental
carcinogens, and cancer survivors with increased risk of a
new primary tumor. Of particular interest appears the
finding that a vaccine against ERBB2, an archetypal class I
oncoantigen, impairs chemical carcinogenesis in hamsters
since it may open a new way to treat healthy persons with a
specific risk of a chemically induced cancer for whom no
active therapeutic option exists at present [64].
Counteraction of immune suppression
The efficacy of vaccines is diminished by the tumor-driven
expansion of immunosuppressive cells, including TReg and
myeloid-derived suppressor cells (MDSC) [50], that results
in both a far less significant immune response and sup-
pression of its effector arm [65, 66]. Strategies that coun-
teract suppression during vaccination can make the
difference between a poorly effective vaccine and a ster-
ilizing one. TReg cells accumulate in both human and
mouse tumors, as well as in secondary lymphoid organs,
and are recruited [67] and expanded by either the prolif-
eration of preexisting TReg cells [68] or the conversion of
CD25-negative T cells [34, 69]. Tumor-driven TReg cell
expansion also changes the tumor-specific T-cell repertoire
[53, 70] and inhibits the reaction of low-avidity T cells
against tumor antigens [53, 69].
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When vaccination is coupled with TReg depletion by the
administration of anti-CD25 monoclonal antibody, a long-
lasting tumor immunity is induced, and the antibody
response is enhanced. In addition, the low-avidity CTL
response against the immunodominant peptide is restored,
due to the freeing of CD8? T cells from TReg constraints
[53]. These effects of TReg depletion render the vaccination
efficacious at tumor stages at which vaccination alone is
ineffective [53]. Similarly, TReg cell functional inhibition,
by means of OX40 triggering, protects mice from sub-
sequent tumor challenge and induces a complete rejection
of already-established nodules [71].
TReg are not the sole suppressive cells than can be
attacked to counteract immune suppression. Myeloid-
derived suppressor cells (MDSC) are an underdeveloped
target of growing importance [72–74]. It has been shown
that powerful vaccines inhibit MDSC [41, 75]; however, a
more direct strategy can be more effective. Four lines of
attack were outlined in a recent review [76]: induction of
MDSC maturation, inhibition of MDSC generation, accu-
mulation, and suppressive function.
The clinical use of antisuppressive approaches will benefit
all cancer patients, in particular more advanced ones, who
frequently display higher levels of immune suppression and
suppressive cells. As novel immunotherapies are first tried in
advanced patients, we think that the success rate of such
clinical trials would be significantly enhanced by the simul-
taneous implementation of counter-suppression approaches.
Conclusions and perspectives
Can these three hallmarks lead to the formulation of immune
procedures effective in tumor therapy? The emerging evi-
dence shows that immune maneuvers can control cancer.
This evidence is still scattered, but a series of recent reports
suggest that immunotherapy is becoming a real option in the
management of cancer patients. Vaccines of various kinds, in
fact, have provided results equal or better than the most
successful conventional treatments in a range of neoplastic
diseases such as lymphomas [77], melanomas [78], prostate,
and lung cancer [79]. These results along with the approval
by US FDA of an initial vaccine for cancer therapy [80] will
certainly spur fresh and even more rational strategies for
vaccines in cancer therapy. It is thus predictable that new
vaccines based on innovative technologies will progres-
sively reach the efficacy of most conventional cancer ther-
apies and spare patients from the devastating side effects of
chemotherapy. In some cases, the cure afforded by a vaccine
may prove to be even more effective, more persistent than
chemotherapy.
It is noteworthy that current preclinical and clinical
results converge on the relevance of antibodies in
antitumor immune responses [63, 81, 82]. In the last
10 years, Herceptin and other mAbs have become effica-
cious new drugs that are commonly used and provide
incredibly high revenues [83].
The mechanism of antitumor activity of mAb is complex
and depends on the targeted antigen. mAb against Class I
and Class II oncoantigens not only functionally inhibit the
activity of their targets and recruit antibody-dependent
killer mechanisms and complement-dependent reactions
but also recruit the host adaptive response and act to some
extent as a vaccine [84, 85]. Despite these important clin-
ical results, most antitumor vaccines are still designed to
trigger only cell-mediated immunity. It is remarkable that a
clinical trial of the first approved vaccine revealed signif-
icant correlations between patient survival and specific
antibody titers, but not T-cell responses [80]. Probably, the
time is ripe to integrate such ‘‘humoral’’ concepts in the
design of new therapeutic cancer vaccines.
In conclusion, appraisal of the immune hallmarks of
cancer, and of the possible countermeasures, opens the doors
not only to widespread cancer immunoprevention but also to
innovative and more efficacious cancer immunotherapies.
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